My story
I have always been passionate about working with disruptive technologies, particularly in healthcare. My background in both pharmacy and business school laid the foundation for this path. I also held various positions across multiple sectors, including venture capital roles at Andera Partners and Turenne Santé, where I initiated the investment in Mablink, which was later acquired by Eli Lilly. I also gained valuable experience as a sell-side analyst at Portzamparc – Groupe BNP Paribas, contributing to the successful IPO of Maat Pharma, the largest biotech IPO of 2021.
In late 2022, I joined Agile Capital Markets, where I leverage my unique combination of academic and professional expertise to deeply understand the science behind each project, offer strategic advice to CEOs, and connect them with the most suitable investors.
I am excited about the future and the opportunities that lie ahead at the dynamic intersection of banking and healthcare.